Novo Nordisk, bluebird bio partner on genome editing in hemophilia

The companies will use Novo Nordisk’s experience with hemophilia and bluebird’s TALENs-based genome editing technology, megaTAL, with a particular focus on hemophilia A. (

1 Star2 Stars3 Stars4 Stars5 Stars (No Ratings Yet)

Leave a Reply

Your email address will not be published. Required fields are marked *